Literature DB >> 3053574

Bactericidal mechanisms of ofloxacin.

C S Lewin1, J T Smith.   

Abstract

Ciprofloxacin and ofloxacin are known to exert a second bactericidal mechanism (termed B) against Escherichia coli which functions even when protein synthesis is inhibited by chloramphenicol or when RNA synthesis is inhibited by rifampicin. However, the bactericidal activity of ciprofloxacin against a coagulase-negative staphylococcus (Staphylococcus warneri) was found to be abolished by chloramphenicol so the 4-quinolone does not exert mechanism B against this species. On the other hand, ofloxacin did exhibit mechanism B against S. warneri because the drug remained bactericidal in the presence of chloramphenicol. When S. aureus was investigated results similar to those observed in S. warneri were obtained throughout the range of clinically achievable concentrations of ofloxacin and ciprofloxacin. Ofloxacin seems to exhibit mechanism B against the staphylococci while ciprofloxacin does not. This may explain why ciprofloxacin is more potent than ofloxacin against Gram-negative bacteria but against staphylococci both drugs are equipotent.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3053574     DOI: 10.1093/jac/22.supplement_c.1

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  18 in total

Review 1.  The mode of action of quinolones: the paradox in activity of low and high concentrations and activity in the anaerobic environment.

Authors:  C S Lewin; I Morrissey; J T Smith
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-04       Impact factor: 3.267

2.  Antagonistic effect of rifampin on the efficacy of high-dose levofloxacin in staphylococcal experimental foreign-body infection.

Authors:  O Murillo; M E Pachón; G Euba; R Verdaguer; F Tubau; C Cabellos; J Cabo; F Gudiol; J Ariza
Journal:  Antimicrob Agents Chemother       Date:  2008-08-01       Impact factor: 5.191

3.  Moxifloxacin lethality against Mycobacterium tuberculosis in the presence and absence of chloramphenicol.

Authors:  Muhammad Malik; Karl Drlica
Journal:  Antimicrob Agents Chemother       Date:  2006-08       Impact factor: 5.191

Review 4.  Ofloxacin. A reappraisal of its antimicrobial activity, pharmacology and therapeutic use.

Authors:  P A Todd; D Faulds
Journal:  Drugs       Date:  1991-11       Impact factor: 9.546

5.  Decimal assay for additivity of drugs permits delineation of synergy and antagonism.

Authors:  C C Sanders; W E Sanders; E S Moland
Journal:  Antimicrob Agents Chemother       Date:  1993-02       Impact factor: 5.191

Review 6.  Ofloxacin clinical pharmacokinetics.

Authors:  K C Lamp; E M Bailey; M J Rybak
Journal:  Clin Pharmacokinet       Date:  1992-01       Impact factor: 6.447

7.  Contribution of permeability and sensitivity to inhibition of DNA synthesis in determining susceptibilities of Escherichia coli, Pseudomonas aeruginosa, and Alcaligenes faecalis to ciprofloxacin.

Authors:  J Bedard; S Chamberland; S Wong; T Schollaardt; L E Bryan
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

8.  Identification of a pKM101 region which confers a slow growth rate and interferes with susceptibility to quinolone in Escherichia coli AB1157.

Authors:  B Clerch; E Rivera; M Llagostera
Journal:  J Bacteriol       Date:  1996-10       Impact factor: 3.490

9.  Pharmacodynamics of once- or twice-daily levofloxacin versus vancomycin, with or without rifampin, against Staphylococcus aureus in an in vitro model with infected platelet-fibrin clots.

Authors:  S M Palmer; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

10.  Pharmacodynamics of levofloxacin, ofloxacin, and ciprofloxacin, alone and in combination with rifampin, against methicillin-susceptible and -resistant Staphylococcus aureus in an in vitro infection model.

Authors:  S L Kang; M J Rybak; B J McGrath; G W Kaatz; S M Seo
Journal:  Antimicrob Agents Chemother       Date:  1994-12       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.